Health Care
Commentary
What’s The GLP-1 Black Market, How Big a Threat Is It?
A black market in weight-loss drugs is flourishing in plain sight. Rogue pharmacies and telehealth firms are flooding the United States with unauthorized knock-offs of semaglutide, tirzepatide, and other glucagon-like peptide-1 drugs. Better known by brand names like Ozempic, Wegovy, Mounjaro, and Zepbound, the knock-off versions of these drugs are ...
Commentary
Generics Must Compete On Price, Not Safety
America’s generic drug market is one of our greatest health policy successes. Today, 91% of all prescriptions in the U.S. are filled with generics. That dominance saves patients and taxpayers hundreds of billions of dollars every year—and it also drives innovation. Drugmakers know their monopoly on a new treatment will ...
Commentary
The Inflationary Effect of Drug Price Controls
In a bill chock full of bad policies, the drug pricing provision of the Inflation Reduction Act stands out as particularly troubling. This provision establishes a negotiation process to set a Maximum Fair Price (MFP) on selected drugs for Medicare patients. Because the legislation calls the MFP a negotiation doesn’t ...
Commentary
The Trump Administration Is Reviving Its Worst Drug Pricing Policies
It’s been a big year for revivals. There’s a new Jurassic Park movie, a reunion tour featuring 1990s rock band Oasis, and a Harry Potter television series in the works. President Trump is also looking to revive some of the policies he tried to enact during his first term. He ...
Blog
Pulling mRNA Research Funding Undermines Future Innovations
Pulling mRNA Research Funding Undermines Future Innovations by Wayne Winegarden | August 15, 2025 The U.S. is a global leader in the innovative pharmaceutical industry, in part, because the public and private sectors effectively fulfill their complimentary roles. The federal government funds basic research that expands our knowledge base; the ...
Commentary
Is a Primary Care Revolution Dawning?
Americans in need of primary care will soon have more options, thanks to the One Big Beautiful Bill Act (OBBBA). The recently passed law allows patients to use money from tax-advantaged health savings accounts to pay for direct primary care for the first time. Direct primary care, or DPC, is ...
Commentary
Let the Obamacare subsidies expire
As members of Congress return to their districts this month, they may receive earfuls about extending the Biden administration‘s enhanced subsidies for Obamacare, which are scheduled to expire at the end of this year. Pundits warn that, unless Congress extends the subsidies, premiums in the individual market could increase by ...
Commentary
Drugmakers Are Embracing Direct-To-Consumer Sales. That’s Fantastic News For Patients.
Several Big Pharma companies have started selling their drugs directly to consumers (DTC). This shift — driven in part by President Trump’s push for lower drug prices and fewer middlemen — has garnered relatively little media coverage. But the implications for American patients, employers, and the healthcare system as a ...
Commentary
Obamacare Premiums Are Climbing Again. But Americans Finally Have An Alternative
Get ready to pay more for insurance coverage through Obamacare’s exchanges. The median premium increase for plans from 105 insurers in 19 states and the District of Columbia will be 15% in 2026, according to the Kaiser Family Foundation. That’s more than double the median premium increase of 7% this ...
Commentary
Drug Tariffs Cure Nothing and Are a Tax Increase
President Donald Trump has made no secret of his desire for sweeping tariffs on pharmaceuticals. Last month, the president threatened tariffs as high as 200% on imported drugs. The trade deal with the European Union (EU) finalized July 27 includes a 15% levy on medicines imported from the continent. Drug ...
What’s The GLP-1 Black Market, How Big a Threat Is It?
A black market in weight-loss drugs is flourishing in plain sight. Rogue pharmacies and telehealth firms are flooding the United States with unauthorized knock-offs of semaglutide, tirzepatide, and other glucagon-like peptide-1 drugs. Better known by brand names like Ozempic, Wegovy, Mounjaro, and Zepbound, the knock-off versions of these drugs are ...
Generics Must Compete On Price, Not Safety
America’s generic drug market is one of our greatest health policy successes. Today, 91% of all prescriptions in the U.S. are filled with generics. That dominance saves patients and taxpayers hundreds of billions of dollars every year—and it also drives innovation. Drugmakers know their monopoly on a new treatment will ...
The Inflationary Effect of Drug Price Controls
In a bill chock full of bad policies, the drug pricing provision of the Inflation Reduction Act stands out as particularly troubling. This provision establishes a negotiation process to set a Maximum Fair Price (MFP) on selected drugs for Medicare patients. Because the legislation calls the MFP a negotiation doesn’t ...
The Trump Administration Is Reviving Its Worst Drug Pricing Policies
It’s been a big year for revivals. There’s a new Jurassic Park movie, a reunion tour featuring 1990s rock band Oasis, and a Harry Potter television series in the works. President Trump is also looking to revive some of the policies he tried to enact during his first term. He ...
Pulling mRNA Research Funding Undermines Future Innovations
Pulling mRNA Research Funding Undermines Future Innovations by Wayne Winegarden | August 15, 2025 The U.S. is a global leader in the innovative pharmaceutical industry, in part, because the public and private sectors effectively fulfill their complimentary roles. The federal government funds basic research that expands our knowledge base; the ...
Is a Primary Care Revolution Dawning?
Americans in need of primary care will soon have more options, thanks to the One Big Beautiful Bill Act (OBBBA). The recently passed law allows patients to use money from tax-advantaged health savings accounts to pay for direct primary care for the first time. Direct primary care, or DPC, is ...
Let the Obamacare subsidies expire
As members of Congress return to their districts this month, they may receive earfuls about extending the Biden administration‘s enhanced subsidies for Obamacare, which are scheduled to expire at the end of this year. Pundits warn that, unless Congress extends the subsidies, premiums in the individual market could increase by ...
Drugmakers Are Embracing Direct-To-Consumer Sales. That’s Fantastic News For Patients.
Several Big Pharma companies have started selling their drugs directly to consumers (DTC). This shift — driven in part by President Trump’s push for lower drug prices and fewer middlemen — has garnered relatively little media coverage. But the implications for American patients, employers, and the healthcare system as a ...
Obamacare Premiums Are Climbing Again. But Americans Finally Have An Alternative
Get ready to pay more for insurance coverage through Obamacare’s exchanges. The median premium increase for plans from 105 insurers in 19 states and the District of Columbia will be 15% in 2026, according to the Kaiser Family Foundation. That’s more than double the median premium increase of 7% this ...
Drug Tariffs Cure Nothing and Are a Tax Increase
President Donald Trump has made no secret of his desire for sweeping tariffs on pharmaceuticals. Last month, the president threatened tariffs as high as 200% on imported drugs. The trade deal with the European Union (EU) finalized July 27 includes a 15% levy on medicines imported from the continent. Drug ...
